Juca Rafaela Hamada, Bregion Pedro Bicudo, de Oliveira-Filho Josélio Rodrigues, da Rocha Soares Giulia Almiron, Juca Sofia Hamada, Ivano Victor Kenzo, Cazzo Everton
State University of Campinas, Campinas, Brazil.
Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil.
Obes Surg. 2025 Feb;35(2):587-601. doi: 10.1007/s11695-025-07669-z. Epub 2025 Jan 8.
Obesity is a significant risk factor for chronic kidney disease (CKD), with metabolic bariatric surgery offering potential renal benefits. However, there is limited comparative data on the impact of Roux-en-Y gastric bypass (RYGB) versus laparoscopic sleeve gastrectomy (LSG) on renal function in individuals with obesity without end-stage renal disease (ESRD). The objective of this study was to compare renal function outcomes following RYGB and LSG in patients with obesity, focusing on estimated glomerular filtration rate (eGFR), serum creatinine, albumin-creatinine ratio (ACR), and serum cystatin C.
A systematic review and meta-analysis were conducted following Cochrane and PRISMA guidelines. Data from 17 observational studies (n = 3339) were analyzed. Primary outcomes included changes in eGFR, ACR, serum creatinine, and cystatin C. Secondary outcomes included excess weight loss (%EWL) and total weight loss (%TWL). Statistical analysis involved fixed and random-effects models based on heterogeneity levels.
RYGB demonstrated significant improvements in eGFR (SMD = - 0.71; 95% CI - 0.89 to - 0.52, p < 0.00001) and serum cystatin C (MD = - 0.10; 95% CI - 0.17 to - 0.03, p = 0.004) compared to LSG. No significant differences were found for serum creatinine (MD = - 1.06; 95% CI - 4.42 to 2.30, p = 0.54) or ACR (MD = 1.95; 95% CI - 0.39 to 4.29, p = 0.10). RYGB also showed greater long-term weight loss, particularly at 5 years (%EWL: MD = 22.00; 95% CI 6.56 to 37.44, p = 0.005).
RYGB offers similar renal improvements with superior weight loss compared to LSG in individuals with obesity without ESRD. These findings emphasize the need for personalized treatment approaches and further research to validate these outcomes.
肥胖是慢性肾脏病(CKD)的一个重要危险因素,代谢性减重手术可能对肾脏有益。然而,关于 Roux-en-Y 胃旁路术(RYGB)与腹腔镜袖状胃切除术(LSG)对非终末期肾病(ESRD)肥胖个体肾功能影响的比较数据有限。本研究的目的是比较肥胖患者接受 RYGB 和 LSG 后的肾功能结果,重点关注估计肾小球滤过率(eGFR)、血清肌酐、白蛋白肌酐比值(ACR)和血清胱抑素 C。
按照 Cochrane 和 PRISMA 指南进行系统评价和荟萃分析。分析了 17 项观察性研究(n = 3339)的数据。主要结局包括 eGFR、ACR、血清肌酐和胱抑素 C 的变化。次要结局包括超重减轻百分比(%EWL)和总体重减轻百分比(%TWL)。统计分析根据异质性水平采用固定效应模型和随机效应模型。
与 LSG 相比,RYGB 在 eGFR(标准化均数差[SMD] = -0.71;95%置信区间[-0.89 至 -0.52],p < 0.00001)和血清胱抑素 C(平均差[MD] = -0.10;95%置信区间[-0.17 至 -0.03],p = 0.004)方面有显著改善。血清肌酐(MD = -1.06;95%置信区间[-4.42 至 2.30],p = 0.54)或 ACR(MD = 1.95;95%置信区间[-0.39 至 4.29],p = 0.10)无显著差异。RYGB 还显示出更大的长期体重减轻,尤其是在 5 年时(%EWL:MD = 22.00;95%置信区间[6.56 至 37.44],p = 0.005)。
对于非 ESRD 的肥胖个体,RYGB 与 LSG 相比,在改善肾脏功能方面相似,但体重减轻效果更佳。这些发现强调了个性化治疗方法的必要性以及进一步研究以验证这些结果。